Vital, Carolina Graziani 
; Maranhão, Raul Cavalcante ; Freitas, Fatima Rodrigues ; Eyll, Brigitte Marie Van; Graziani, Silvia Regina
Fonte: Journal of Bone Oncology. Unidade: FCF
Assuntos: NANOPARTÍCULAS, NEOPLASIAS ÓSSEAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VITAL, Carolina Graziani et al. Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: lack of toxicity and therapeutic benefits. Journal of Bone Oncology, v. 34, p. 1-7, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jbo.2022.100431. Acesso em: 30 set. 2024.APA
Vital, C. G., Maranhão, R. C., Freitas, F. R., Eyll, B. M. V., & Graziani, S. R. (2022). Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: lack of toxicity and therapeutic benefits. Journal of Bone Oncology, 34, 1-7. doi:10.1016/j.jbo.2022.100431NLM
Vital CG, Maranhão RC, Freitas FR, Eyll BMV, Graziani SR. Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: lack of toxicity and therapeutic benefits [Internet]. Journal of Bone Oncology. 2022 ;34 1-7.[citado 2024 set. 30 ] Available from: https://doi.org/10.1016/j.jbo.2022.100431Vancouver
Vital CG, Maranhão RC, Freitas FR, Eyll BMV, Graziani SR. Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: lack of toxicity and therapeutic benefits [Internet]. Journal of Bone Oncology. 2022 ;34 1-7.[citado 2024 set. 30 ] Available from: https://doi.org/10.1016/j.jbo.2022.100431
